Chapter 5 106 References 1. Del Gobbo LC, Imamura F, Wu JHY, de Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2013;98(1):160-173. doi:10.3945/ ajcn.112.053132 2. Joris PJ, Plat J, Bakker SJ, Mensink RP. Long-term magnesium supplementation improves arterial stiffness in overweight and obese adults: results of a randomized, double-blind, placebo-controlled intervention trial. Am J Clin Nutr. 2016;103(5):1260-1266. doi:10.3945/ ajcn.116.131466 3. Whitworth JA, Williamson PM, Mangos G, Kelly JJ. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag. 2005;1(4):291-299. doi:10.2147/vhrm.2005.1.4.291 4. Crawford AA, Soderberg S, Kirschbaum C, et al. Morning plasma cortisol as a cardiovascular risk factor: findings from prospective cohort and Mendelian randomization studies. Eur J Endocrinol. 2019;181(4):429-438. doi:10.1530/EJE-19-0161 5. Battocchio M, Rebellato A, Grillo A, et al. Ambulatory Arterial Stiffness Indexes in Cushing’s Syndrome. Horm Metab Res. 2017;49(03):214-220. doi:10.1055/s-0043-100385 6. Baykan M, Erem C, Gedikli Ö, et al. Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing’s Syndrome. Endocrine. 2007;31(3):300-304. doi:10.1007/ s12020-007-0033-8 7. Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med. 2005;202(4):517-527. doi:10.1084/jem.20050119 8. Westerbacka J, Yki-Järvinen H, Vehkavaara S, et al. Body Fat Distribution and Cortisol Metabolism in Healthy Men: Enhanced 5β-Reductase and Lower Cortisol/Cortisone Metabolite Ratios in Men with Fatty Liver. J Clin Endocrinol Metab. 2003;88(10):4924-4931. doi:10.1210/jc.2003-030596 9. Wilson PWF, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112(20):3066-3072. doi:10.1161/CIRCULATIONAHA.105.539528 10. Tomlinson JW, Walker EA, Bujalska IJ, et al. 11β-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response. Endocr Rev. 2004;25(5):831-866. doi:10.1210/er.2003-0031 11. Edwards CR, Stewart PM, Burt D, et al. Localisation of 11 beta-hydroxysteroid dehydrogenase- -tissue specific protector of the mineralocorticoid receptor. Lancet (London, England). 1988;2(8618):986-989. doi:10.1016/s0140-6736(88)90742-8 12. Chapman K, Holmes M, Seckl J. 11β-Hydroxysteroid Dehydrogenases: Intracellular GateKeepers of Tissue Glucocorticoid Action. Physiol Rev. 2013;93(3):1139-1206. doi:10.1152/ physrev.00020.2012 13. Kerstens, Riemens, Sluiter, Pratt, Wolthers, Dullaart. Lack of relationship between 11betahydroxysteroid dehydrogenase setpoint and insulin sensitivity in the basal state and after 24h of insulin infusion in healthy subjects and type 2 diabetic patients. Clin Endocrinol (Oxf). 2000;52(4):403-411. doi:10.1046/j.1365-2265.2000.00975.x 14. Palermo M, Shackleton CHL, Mantero F, Stewart PM. Urinary free cortisone and the assessment of 11beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf). 1996;45(5):605-611. doi:10.1046/j.1365-2265.1996.00853.x
RkJQdWJsaXNoZXIy MTk4NDMw